AZ&Me™ Prescription Savings Program for People with Medicare Part D Removes Out-of-Pocket Spend Requirement
(NYSE:AZN) today announced that it is simplifying the enrollment
process for the AZ&Me™ Prescription Savings Program for people with
Medicare Part D by removing an out-of-pocket spend requirement.
As of Jan. 1, the program will no longer require that people with
Medicare prescription drug coverage spend 3 percent of their annual
household income on out-of-pocket costs for prescription medicines
within the calendar year to qualify.
Those who meet all of the other program eligibility requirements may
begin receiving their AstraZeneca medicines for free upon successfully
completing the enrollment process. To be eligible for the program, a
Medicare beneficiary must:
Be enrolled in Medicare Part D.
Have an annual household income at or below $35,000 for individuals or
$48,000 for couples.
Not be enrolled in the Medicare Limited Income Subsidy.
"We regularly evaluate how we can simplify our program enrollment
process and saw an opportunity to do so for people with Medicare
prescription drug coverage," said Jennifer McGovern, Director, AZ&Me
Prescription Savings Programs. "Removing the out-of-pocket spend
requirement means that people will no longer have to gather
documentation from their pharmacy before completing their enrollment,
saving them time and helping them get their AstraZeneca medicines
AstraZeneca has offered prescription savings programs for 34 years and
offers one of the industry’s most generous programs. The company will
continue to make program enhancements that better serve patients and the
advocates who help them.
"Prescription assistance programs help fill an important need for many
people who have Medicare Part D coverage, but may not be able to access
all of their medicines because of limited financial resources," said
Nora Dowd Eisenhower, senior vice president for economic security and
director of the Center for Benefits Access, National Council on Aging.
"We salute AstraZeneca for its continued leadership in patient
assistance and will use this opportunity to remind Medicare
beneficiaries, caregivers and advocates that these kinds of programs are
a helpful resource for many who don’t qualify for extra help through the
Medicare Limited Income Subsidy."
AstraZeneca is a global, innovation-driven biopharmaceutical business
with a primary focus on the discovery, development and commercialization
of prescription medicines for gastrointestinal, cardiovascular,
neuroscience, respiratory and inflammation, oncology and infectious
disease. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide.
For more information about AstraZeneca in the U.S. or our AZ&Me™
Prescription Savings programs, please visit: www.astrazeneca-us.com or
call 1-800-AZandMe (292-6363).
AstraZeneca Media Inquiries: Lynn Shepherd, 302-885-8911